Friday tips round-up: Misys, UK Mail, Intercede

Misys is in good health but the Independent says it has had a very good run from these shares and anyone who got in below 129.5p could happily take profits. However, that would miss out on a banking recovery, which will happen before too long, so hold.UK Mail has a low-cost network, growing market share ? and, aside from its push into packets, other initiatives such as retail logistics and "imail" (a hybrid between e-mail and letters) through which it should be able to increase sales. It also has forecast net cash of £15 million, raising the prospect of a rise in its already-generous dividend payout ? which currently provides a 5.1 per cent yield. At 333½p, up 15p, or 14 times earnings, hold on, says the Times.Shares in Intercede fell when the company, which makes software that dovetails with identity card systems, said its pre-exceptional operating profits for the full year would miss market expectations. Time to sell, then? Maybe not. At 10.1 times FinnCap's full-year forecasts, it is not at all pricey so the Independent is happy to keep buying.Yesterday's first-half figures show IBT continues to deliver increases in net asset value (NAV) ? up 8 per cent to 164p in the six months to March 31. Helped by clarity over US healthcare reforms, and a Japanese hostile bid for OSI, one of its holdings, NAV has since risen further ? to 178p.The case from here is that half a dozen of IBT's big American stocks, such as Celgene and Vertex, will report important trial results in 2010. Meanwhile, its unquoted portfolio is now of a sufficient maturity to start providing an exit. Above all, American biotech stocks, at 14 times earnings, remain inexpensive ? even more so given that, at 139¾p, IBT sits at a 22 per cent discount to NAV, and will benefit from sterling weakness. Buy, says the Times.At 150½p, up 2p, Alternative Networks shares have outperformed the FTSE all-share index by 13 per cent over the past three months. However, at nine times FinnCap's current-year forecasts, and providing a dividend yield of 5.7 per cent, they are not stretched. Buy, says the Times.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information. Int.biotech. Intercede